Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Status:
RECRUITING
Trial end date:
2034-12-31
Target enrollment:
Participant gender:
Summary
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.
The names of the study drugs involved in this study are:
* Iberdomide (a type of cereblon E3 ligase modulator)
* Elotuzumab (a type of monoclonal antibody)
* Dexamethasone (a type of steroid)